2024 was a year of massive growth at Bora. We hit record high revenues and net profits while we expanded into specialty pharma with Upsher-Smith and Pyros, strengthened CDMO capabilities with the addition of one of the largest small molecule sites in the US, a Maryland-based sterile injectable facility, and formed a strategic partnership with Tanvex to secure large molecule drug substance CDMO capability. Please join us in celebrating another milestone for Bora. We look forward to seeing the accumulated momentum from carefully executing our dual-engine strategy to be translated into real impacts to the industry and patients worldwide. Bora will host an English online earnings call on March 10 at 8:30 PM Taiwan time/7:30AM EST. Listen here: https://bit.ly/3FeGPjl
